TRANSPERINEAL FUSION PROSTATE BIOPSY – 06/03/2025 HISTOPATHOLOGICAL EXAMINATION REPORT Date of Diagnosis: 13/03/2025...

Understanding Your Prostate Cancer Diagnosis

I can see you've received your biopsy results from [date removed]. This is significant information, and I want to help you understand what these findings mean in educational context. Let me walk through your pathology report carefully.

---

Your Biopsy Overview

Your transperineal fusion biopsy sampled three different areas of your prostate:

| Sample | Location | Finding | |--------|----------|---------| | 3393/25 | Lesion (LEFT) - the suspicious area from MRI | Adenocarcinoma present | | 3394/25 | Systematic (LEFT) - routine sampling | Adenocarcinoma present | | 3395/25 | Systematic (RIGHT) - routine sampling | Not mentioned in report |

Bottom line: Cancer was found in samples from your left prostate lobe.

---

Understanding Your Gleason Score & Grade Group

This is crucial information. Let me explain what these terms mean:

What is Gleason Grading?

The Gleason score describes how abnormal your cancer cells look under the microscope. Pathologists assign patterns (3, 4, or 5) based on cell organization:

• Pattern 3: Cells still look relatively organized (lower grade)
• Pattern 4: Cells are more disorganized, fused together (intermediate grade)
• Pattern 5: Cells are very disorganized (highest grade)

The Gleason score combines the two most common patterns found in your tissue.

Your Two Different Gleason Scores

Sample 3393 (Lesion from MRI-suspicious area):

• Gleason Score: 3+4 = 7
• Primary pattern: 3 (90% of cancer)
• Secondary pattern: 4 (10% of cancer)
• Grade Group: 2 (intermediate risk)
• Tumor length: 3 mm
• Occupies: 6% of tissue sampled
• Perineural invasion: Present (cancer cells near nerves)

Sample 3394 (Systematic sampling, left side):

• Gleason Score: 3+3 = 6
• Pattern: 3 (all cancer cells)
• Grade Group: 1 (lower risk)
• Tumor length: 1.5 mm
• Occupies: <5% of tissue sampled
• Perineural invasion: Present

What This Means

You have two different cancer foci (separate areas) in your left prostate:

1. The MRI-detected lesion shows a 3+4 Gleason score (Grade Group 2)—this is intermediate-grade cancer
2. The systematic sampling found a 3+3 Gleason score (Grade Group 1)—this is lower-grade cancer

Both areas show perineural invasion, meaning cancer cells are present near nerve fibers. This is a finding your oncologist will consider in treatment planning.

---

How NCCN Guidelines Classify Your Disease

According to NCCN Guidelines for Prostate Cancer (Version 2.2026), your cancer would be classified based on:

• PSA level: 5.14 ng/mL (slightly elevated)
• Gleason/Grade Group: Grade Group 2 (from the higher-grade lesion)
• Clinical stage: Clinically localized (T1c, N0, M0)—cancer found on biopsy, not palpable on exam

This places you in the UNFAVORABLE INTERMEDIATE-RISK GROUP according to NCCN risk stratification, because:

• You have Grade Group 2 disease (Grade Group ≥2 moves you from favorable to unfavorable intermediate-risk)
• Your PSA is in the intermediate range
• Cancer is present in multiple cores

---

What You Need to Know About Your Diagnosis

Important Clarifications:

✅ This is early-stage, localized prostate cancer — it hasn't spread to lymph nodes or distant sites based on your imaging

✅ The cancer volume is small — 3 mm maximum length in the lesion, <5% of tissue involved

✅ Grade Group 2 is intermediate — not the lowest risk, but not the highest either. According to NCCN Guidelines, Grade Group 2 cancers have intermediate potential for progression

✅ Perineural invasion is noted — this is a pathologic feature your doctor will factor into treatment decisions

What You Still Need:

Before your treatment plan is finalized, your oncologist will likely want:

1. Staging imaging — CT or MRI of pelvis/abdomen to confirm no lymph node involvement
2. Risk assessment tools — Possibly genomic testing (like Decipher or Prolaris) to further refine your prognosis
3. Life expectancy estimation — Your overall health and expected lifespan inform treatment recommendations
4. Complete clinical picture — Your age (71), comorbidities, and functional status

---

Treatment Options for Unfavorable Intermediate-Risk Prostate Cancer

According to NCCN Guidelines, for patients in your risk group with life expectancy >10 years, typical options include:

Primary Treatment Approaches:

1. Radiation Therapy (RT) + Androgen Deprivation Therapy (ADT)

• External beam radiation to the prostate
• Hormone therapy (ADT) for 4-6 months
• This is a common approach for intermediate-risk disease

2. Radical Prostatectomy (RP)

• Surgical removal of the entire prostate
• May include pelvic lymph node dissection
• Appropriate if you're healthy enough for surgery

3. Active Surveillance (with caution)

• Close monitoring with PSA and imaging
• NCCN notes: Active surveillance of unfavorable intermediate-risk disease is not recommended in patients with life expectancy >10 years (Category 1 recommendation)
• However, some patients with favorable features within the intermediate group may discuss this

---

Questions to Ask Your Oncologist

Now that you have a diagnosis, these questions will help you understand your treatment options:

1. "Based on my Grade Group 2 cancer with perineural invasion, do you recommend radiation + hormone therapy or surgery? What are the pros and cons for my specific situation?"

2. "Should I have any additional staging imaging (CT or MRI) before we finalize treatment, and do you recommend genomic testing to further assess my prognosis?"

3. "If you recommend radiation, how many weeks of treatment, and how long would I need hormone therapy?"

4. "What are the potential side effects of each treatment option, and how might they affect my quality of life?"

5. "What is my expected outcome with each treatment approach, and how will we monitor for recurrence after treatment?"

6. "Are there any clinical trials I should consider?" (Search ClinicalTrials.gov for intermediate-risk prostate cancer trials in your area)

7. "How often will I need PSA monitoring and imaging after treatment, and what PSA level would trigger further evaluation?"

---

Important Context from NCCN Guidelines

According to NCCN Guidelines for Prostate Cancer, for unfavorable intermediate-risk disease:

• Monitoring is preferred for adverse features — Your perineural invasion and Grade Group 2 are considered adverse features
• Treatment is recommended — Rather than observation, active treatment is typically advised
• Combination therapy is standard — Radiation + ADT is a Category 1 (most strongly recommended) approach for your risk group
• Life expectancy matters — At age 71, your life expectancy will influence treatment intensity

---

Next Steps

1. Schedule an oncology consultation if you haven't already—a medical oncologist or radiation oncologist will review your pathology and imaging
2. Bring your questions to that appointment
3. Ask about staging — Confirm whether additional imaging is needed
4. Discuss genomic testing — This can help further refine your prognosis
5. Understand your options — Get clear explanations of each treatment approach

---

Key Takeaway

You have early-stage, intermediate-grade prostate cancer that is localized to the prostate gland. This is treatable, and NCCN Guidelines recommend active treatment